# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company ...
– 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of res...
- SEC Filing
– Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin– Trial combi...
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(2.02) per share which beat the analyst consensus estimate of $(3...
Patent, once issued, will provide composition protection through 2040, with potential for additional term extensionAnnamycin is...
Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13)Ful...